Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ziprasidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 13/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 11/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | GOT1 | P17174 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ziprasidone SCHEMBL28028 | 1.00 | HTR2A (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL4774002 | 1.00 | HTR2A (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL30354044 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL3139060 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL122876 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL5859456 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL3143295 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL4914143 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL6599516 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL374870 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4203942-B1 | IBRUTINIB FOR USE IN TREATING COCAINE USE DISORDER AND RELATED CONDITIONS | UNIV EMORY (US) | 2026-04-15 | — | — | EP | claimed |
| EP-3713986-B1 | COMPOSITION | REBIO TECH OY (FI) | 2026-04-01 | — | — | EP | claimed |
| EP-3194027-B1 | COMPOSITIONS FOR USE IN TREATING PSYCHOTIC DISORDERS | SOUND PHARMACEUTICALS INCORPORATED (US) | 2026-02-11 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4049681-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC DRUG AND A VMAT2 INHIBITOR AND USES THEREOF | NEUROCRINE BIOSCIENCES INC (US) | 2026-01-07 | — | — | EP | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| EP-3258950-B1 | ALZHEIMER ABETA PEPTIDE BINDING POLYPEPTIDE | AMYLONIX AB (SE) | 2025-10-29 | — | — | EP | claimed |
| EP-4223760-B1 | HETEROAROMATIC NMDA RECEPTOR MODULATOR AND USES THEREOF | NOVARTIS AG (CH) | 2025-06-04 | — | — | EP | claimed |
| US-20250120908-A1 | ORAL FILM FORMULATION FOR MODULATING ABSORPTION PROFILE | INTELGENX CORP. (CA) | 2025-04-17 | — | — | US | claimed |
| EP-4057999-B1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-12-13 | — | — | EP | claimed |
| EP-3843705-B1 | PREPARATION OF NANOSUSPENSION COMPRISING NANOCRYSTALS OF ACTIVE PHARMACEUTICAL INGREDIENTS WITH LITTLE OR NO STABILIZING AGENTS | CENTRE NAT RECH SCIENT (FR) | 2023-11-29 | — | — | EP | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| EP-3125893-B1 | DEUTERATED HETEROCYCLE FUSED GAMMA-CARBOLINES AS ANTAGONISTS OF 5-HT2A RECEPTORS | INTRA CELLULAR THERAPIES INC (US) | 2023-09-20 | — | — | EP | claimed |
| EP-3697386-B1 | LIQUID COMPOSITIONS FOR PERORAL USE COMPRISING PHOSPHATIDYLGLYCEROL DERIVATIVES AND THIXOTROPIC EXCIPIENTS FOR TREATING CARDIAC CHANNELOPATHIES CAUSED BY PHARMACOLOGICAL AGENTS | SIGNPATH PHARMA INC (US) | 2023-07-26 | — | — | EP | claimed |
| EP-3319613-B1 | USE OF AMINE CARBOXYBORANES AS THERAPEUTIC DELIVERY OF CARBON MONOXIDE AND AS GENERAL DRUG DELIVERY SYSTEM IN THE PRESENCE OF REACTIVE OXYGEN SPECIES | UNIV NEW YORK STATE RES FOUND (US) | 2023-02-22 | — | — | EP | claimed |
| US-20230047314-A1 | ORAL FILM FORMULATION FOR MODULATING ABSORPTION PROFILE | INTELGENX CORP. (CA) | 2023-02-16 | — | — | US | claimed |
| US-11471406-B2 | Oral film formulation for modulating absorption profile | INTELGENX CORP. (CA) | 2022-10-18 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3753966-B1 | AMPHIPHILIC BLOCK COPOLYMER, PREPARATION METHOD THEREOF AND NANOMICELLE DRUG-LOADING SYSTEM | SHANGHAI BEST LINK BIOSCIENCE LLC (CN) | 2022-05-25 | — | — | EP | claimed |